


Benzobisimidazole Cruciform Fluorophores

Ha T. M. Le, Nadia S. El-Hamdi, and Ognjen Š. Miljanić*

Department of Chemistry, University of Houston, 112 Fleming Building, Houston, Texas 77204-5003, United States

Supporting Information

ABSTRACT: A series of 11 cross-conjugated cruciform fluorophores based on a benzobisimidazole nucleus has been synthesized and characterized. Like in their previously reported benzobisoxazole counterparts, the HOMOs of these new fluorophores are localized along the vertical bisethynylbenzene axes, while their LUMOs remain relatively delocalized across the molecule, except in cruciforms substituted with electron-withdrawing groups along the vertical axis. Benzobisimidazole cruciforms exhibit a pronounced response to deprotonation in their UV/vis absorption and emission spectra, but their response to protonation is significantly attenuated.



INTRODUCTION

Cross-conjugated molecular cruciforms¹ have been the subject of much scrutiny in recent years as their modular optoelectronic properties make them versatile elements in sensing and molecular electronics applications. Nuckolls,² Jeffries-EL,³ and we⁴ have extensively studied molecular cruciforms based on the central benzobisoxazole motif, represented by structure 1 (Figure 1). Our group has




Figure 1. Previous examples of fluorophores based on cross-conjugated benzobisoxazole (1) and benzimidazole (2) geometries and benzobisimidazole motif (3).

demonstrated that benzobisoxazole cruciforms represent a viable fluorescent sensor for a broad variety of analytes and that they are capable of detecting minute structural differences between those analytes.^{4d,f} In a related effort, we have shown that cruciforms can be “cut in half” and that the oxazole nucleus can be replaced by an imidazole to give L-shaped half-cruciforms of the general structure 2.⁵ Bielawski et al. have studied fluorophores based on benzobisimidazolium salts represented by general structure 3.⁶

In this paper, we present “the missing link” in this series of fluorophores: the X-shaped benzobisimidazole-based cruciforms 4a–l (Scheme 1). These new fluorophores are direct

analogues of 1 in which the two oxazole nuclei have been replaced with imidazoles.

RESULTS AND DISCUSSION


Synthesis. Despite the structural similarity between 1 and 4, their syntheses had to be approached quite differently. Cruciforms 1 could be easily elaborated from the readily available 2,5-diamino-3,6-dibromobenzene-1,4-diol,⁷ whose *o*-aminophenol functionalities engaged in acyl condensation to generate the horizontal axis, while the two bromine substituents reacted in a Sonogashira coupling to establish the vertical axis. As the corresponding 1,2,4,5-tetraamino-3,6-dibromobenzene⁸ proved difficult to prepare and handle, we chose to begin the synthesis of benzobisimidazole cruciforms with a hydrochloride salt of 1,2,4,5-tetraaminobenzene (5, Scheme 1).⁹ Its condensation with benzoic acid in the presence of polyphosphoric acid (PPA) yielded intermediate 6,⁴ which was then doubly brominated on the central benzene ring with *N*-bromosuccinimide (NBS) to produce compound 7. The vertical axis was established by the subsequent Sonogashira coupling with a terminal alkyne bearing functionalities of interest, yielding cruciforms 4a and 4b (route A, highlighted in dark red in Scheme 1). In an alternative approach (route B, highlighted in blue), the roles of coupling partners were switched: compound 7 was first reacted with tris(isopropylsilyl)acetylene (TIPSA) and then desilylated to reveal two terminal alkyne functionalities in precursor 8. Compound 8 was subsequently functionalized through a second Sonogashira coupling to produce cruciforms 4c–k. Cruciform 4l was obtained after acidic hydrolysis of the tetrahydropyranyl (THP) protecting group in 4k.

It should be noted that this synthetic route was plagued with difficulties. First, compound 5 is very difficult to handle on

Received: March 18, 2015

Published: April 27, 2015

Scheme 1. Synthesis of Benzobisimidazole Cruciforms 4a–l



account of its sensitivity to oxidation and high polarity. Second, analogues of the highly insoluble intermediate **6** bearing other functional groups along the horizontal axis proved difficult to prepare and impossible to purify, and their subsequent bromination yielded mixtures of products. Thus, we were not able to effectively vary the substitution along the horizontal axis of these cruciforms. Finally, the closing Sonogashira couplings proceeded in moderate yields (27–60%), which was likely a consequence of the low solubility of the precursors.

Computational Studies. Frontier molecular orbitals (FMOs) of cruciform **4a–j,l** have been calculated using Gaussian 09W¹⁰ software using the B3LYP hybrid density functional and 3-21G as the basis set. FMOs of two exemplary cruciforms **4a** and **4f** are shown in Figure 2. In both systems, the highest occupied molecular orbital (HOMO) resides dominantly along the vertical axis. As observed previously for the related benzobisoxazole-based cruciforms,³ this vertical localization of the HOMOs is a consequence of orbital properties of the benzobisimidazole core and is largely independent of the substitution. The lowest unoccupied molecular orbital (LUMO) of **4a** is in contrast delocalized across the molecule. In the case of a cruciform substituted with electron-withdrawing groups along the vertical axis, such as **4f** (Figure 2, bottom), the LUMO also resides along the electron-




Figure 2. HOMOs (left) and LUMOs (right) of cruciforms **4a** and **4f** (calculated with Gaussian using B3LYP hybrid density functional and 3-21G basis set).

poor vertical axis of the molecule. As synthetic access to cruciform variants with a different substitution on the horizontal axis was restricted, we were unable to probe the effects of placing strongly electron-withdrawing or electron-donating groups along the horizontal axis.

Optical Properties. Compounds **4a–l** are yellow to red powders with moderate solubility in most common organic solvents. Their ¹H NMR spectra are complicated by facile tautomerization of both imidazoles but are otherwise consistent with their structures. They are highly fluorescent¹¹ in solution and mildly in the solid state when irradiated with a hand-held UV lamp ($\lambda_{\text{exc}} = 365$ nm). UV/vis absorption and fluorescence emission spectra of **4a–j,l** are shown in Figure 3 and summarized in Table 1. UV/vis absorption spectra (Figure 3, top) of all cruciforms are essentially superimposable with a single broad absorption band centered between 380 and 395 nm. The only exception is **4b**, whose absorption spectrum shows an additional band at 425 nm. In their fluorescence emission spectra (Figure 3, bottom), a somewhat greater level of distinction can be achieved. Compound **4b** is a clear outlier, with a relatively featureless emission band at 486 nm. All other cruciforms' emission spectra show two distinct maxima: a more intense one, centered between 426 (for **4e**) and 456 (for **4i**) nm, and a lower intensity band, centered between 452 (for **4e**) and 483 (for **4i**) nm. Most of these trends are visible by the naked eye (see Figure 5 below) in that colors of all cruciforms except **4b** look similar under both UV and visible light.

Optical Response to Acids and Bases. In contrast to benzobisoxazole-based cruciforms, these new benzobisimidazole-based systems are amphoteric and were expected to show significant changes in their UV/vis absorptions and emissions upon both protonation and deprotonation. To experimentally confirm this hypothesis, we performed titrations of **4a–l** with both an acid (trifluoroacetic acid, TFA) and a base (tetrabutylammonium hydroxide, TBAOH) in THF. Full experimental details of these titrations are given in the




Figure 3. Normalized UV/vis absorption (top) and emission (bottom) spectra of cruciforms **4a–j**, **l** in THF. Excitation wavelengths for emission spectra: 335 (**4a**), 348 (**4b**), 336 (**4c**), 337 (**4d**), 333 (**4e**), 339 (**4f–4h**), 330 (**4i–4j**), 337 (**4l**) nm.

Table 1. Optical Properties and Calculated HOMO–LUMO Gaps for Cruciforms **4a–l**

compd	absorption λ_{\max} (nm)	emission λ_{\max} (nm)	Stokes shift (cm ⁻¹)	calcd HOMO–LUMO gap (eV, nm)
4a	386	430	2651	3.02, 411
4b	386	487	5373	3.00, 414
4c	386	432	2759	2.99, 415
4d	385	438	3143	2.91, 426
4e	383	428	2745	3.01, 412
4f	388	451	3600	2.61, 475
4g	392	438	2679	2.99, 415
4h	391	443	3002	2.83, 438
4i	382	458	4344	2.86, 434
4j	395	451	3144	2.90, 428
4l	383	439	3330	2.93, 423

Supporting Information. In general, benzobisimidazole cruciforms show a rather moderate response to acids: with excess acid ($-\log[\text{TFA}] < 1.0$), a blue shift in absorption of up to $\Delta\lambda = -18$ nm was observed. This set of observations could be rationalized by protonation of benzobisimidazole nitrogen atoms ($\text{p}K_{\text{a}} = 5.55$ for benzimidazolium cation)¹² at high acid concentration. The only cruciform with a different response was **4b** (Figure 4, top), whose significantly more basic $-\text{NMe}_2$ groups became protonated at lower concentrations of TFA. In the emission spectra of **4a–j**, small but less consistent changes were observed: for some cruciforms, emission shifted minimally toward the red region, while for others it shifted toward the blue or was quenched.




Figure 4. Exemplary titrations of benzobisimidazole cruciforms with acid (top) and base (bottom). (Top) Changes in UV/vis absorption spectra of cruciform **4b** as a function of added TFA. (Bottom) Fluorescence response of cruciform **4a** to the addition of TBAOH ($\lambda_{\text{exc}} = 335$ nm). Both titrations were performed in THF.

Response of benzobisimidazole cruciforms to bases is much more dramatic. Upon exposure to high concentrations of base ($-\log[\text{TBAOH}] < 2.5$), red shifts in absorption of approximately $\Delta\lambda = 100$ nm occurred for all studied cruciforms and were accompanied by equally significant shifts in the emission (as illustrated for **4a** in Figure 4, bottom); for more acidic **4f**, even lower concentrations of base induced similar shifts. As noticed previously in L-shaped half-cruciforms,⁵ deprotonation of benzobisimidazole's N–H moieties ($\text{p}K_{\text{a}} = 12.78$)¹² causes these dramatic changes in fluorescence.

Most of these changes were detectable by the naked eye as well. Digital photographs of vials containing 10^{-5} M solutions of **4a–j**, **l** under visible and UV light are shown in Figure 5, and the dramatic response of these cruciforms to a base is apparent.

CONCLUSION

In summary, we have synthesized a series of 11 cross-conjugated cruciform fluorophores based on the benzobisimidazole nucleus using a combination of acid-catalyzed condensation and Sonogashira coupling. These materials are fluorescent in the solid state and strongly so in dilute solutions. All of them also show a pronounced red shift upon deprotonation of their imidazole N–H functionalities, while in contrast, their response to acids is much more attenuated. This lack of response is partially a consequence of our inability to synthetically access diverse substitution patterns on the horizontal axis, which in turn meant that we could modulate the LUMO orbitals of **4a–l** only to a limited extent. Thus, unlike in the benzobisoxazole series,^{4g} systems with completely spatially




Figure 5. Acid- and base-induced changes in the colors of 10^{-5} M solutions of cruciforms **4a–j, l** in THF, as observed under visible (top) and UV (bottom) light. For emission color photographs, $\lambda_{\text{exc}} = 365$ nm, shutter speed 0.05 s.

separated FMOs could not be produced and studied. At the same time, it is highly encouraging that almost all of the benzobisimidazole cruciforms maintain a certain level of fluorescence regardless of their protonation state. This feature could be explored in the preparation of, e.g., fluorescent and guest-responsive porous materials, such as zeolitic imidazolate frameworks (ZIFs),¹³ utilizing these cross-conjugated benzobisimidazoles.

EXPERIMENTAL SECTION

General Experimental Methods. All reactions were performed under nitrogen atmosphere in oven-dried glassware. Reagents were purchased from commercial suppliers and used without further purification. Solvents were used as received, except THF and *N,N*-dimethylformamide (DMF), which were degassed by a 30 min nitrogen purge prior to use in Sonogashira couplings. Compounds 1,5-dichloro-2,4-dinitrobenzene¹⁴ and 1,3-diamino-4,6-dinitrobenzene¹⁵ were synthesized according to literature procedures. Triethylamine (Et_3N) was degassed by a 30 min nitrogen purge prior to use. Microwave-assisted reactions were performed in a Biotage Initiator 2.0 microwave reactor, producing monochromatic microwave radiation with the frequency of 2.45 GHz. NMR spectra were obtained on spectrometers with working frequencies (for ^1H nuclei) of 400, 500, and 600 MHz. All ^{13}C NMR spectra were recorded with simultaneous decoupling of ^1H nuclei. ^1H NMR chemical shifts are reported in ppm units relative to the residual signal of the solvent (CDCl_3 : 7.25 ppm, $(\text{CD}_3)_2\text{SO}$: 2.48 ppm, D_2O : 4.79 ppm, $(\text{CD}_3)_2\text{CO}$: 2.05 ppm). All NMR spectra were recorded at 25 °C for samples in CDCl_3 , D_2O , and $(\text{CD}_3)_2\text{CO}$, while samples in $\text{DMSO}-d_6$ were recorded at temperatures ranging from 25 to 90 °C. Mass spectra of compound **7** and 2,6-diphenyl-4,8-bis((triisopropylsilyl)ethynyl)-1,5-dihydrobenzo[1,2-*d*:4,5-*d'*]diimidazole were obtained using magnetic sector CI mass analyzer, while cruciforms **4a–l** were analyzed using a QToF mass analyzer. Melting point measurements were performed in open capillary tubes, and the reported values are uncorrected. Column chromatography was carried out on silica gel 60, 32–63 mesh, and basic aluminum oxide Act. 1, 50–200 μm . Analytical TLC was performed on plastic-backed silica gel IB-F plates and aluminum oxide IB-F plates.

Synthesis of 1,2,4,5-Benzenetetramine Tetrahydrochloride (5). A 1 L Schlenk flask was flushed with nitrogen and charged with

1,3-diamino-4,6-dinitrobenzene¹⁵ (6.00 g, 30.3 mmol), concentrated HCl (311 mL), and EtOH (155 mL). The reaction flask was attached to the condenser and heated at 50 °C with stirring for 10 min. After 10 min, a solution of anhydrous SnCl_2 (52.0 g, 274 mmol) in EtOH (80 mL) was added to the reaction mixture. The beaker containing the SnCl_2 solution was washed with an additional portion of EtOH (40 mL), and the washings were added to the reaction flask. The reaction was heated at 86 °C for 2 d to ensure that the reaction went to completion. The reaction resulted in a white precipitate forming in the flask. After cooling, the solution was filtered and the residue was washed with EtOH to give the product as a light pink solid (8.1 g). The crude product was used without further purification. **5.** IR (neat): 2923 (s, $\tilde{\nu}_{\text{N-H}}$), 2495 (s), 1601 (m, $\tilde{\nu}_{\text{C-C}}$), 1556 (s), 1511 (s, $\tilde{\nu}_{\text{N-H}}$), 1221 (s, $\tilde{\nu}_{\text{C-N}}$), 1127 (m), 1054 (w), 860 (m, $\tilde{\nu}_{\text{C-H}}$) cm^{-1} . ^1H NMR (D_2O , 400 MHz): δ 6.77 (s) ppm. ^{13}C NMR (D_2O , 100 MHz): δ 125.1, 113.5 ppm.

Synthesis of 2,6-Diphenyl-1,5-dihydrobenzo[1,2-*d*:4,5-*d'*]diimidazole (6).⁴⁹ In a 500 mL round-bottom flask equipped with a condenser was heated a mixture of **5** (10.3 g, 36.3 mmol), benzoic acid (17.7 g, 145 mmol), and polyphosphoric acid (PPA, 70 g) to 140 °C. The reaction temperature was slowly increased to 145 °C and maintained at that temperature for 40 h. After the reaction was finished, the mixture was allowed to cool and was then poured into ice–water. Stirring was continued while the mixture was made very basic by the addition of NaOH pellets (pH = 14). The precipitate was filtered, washed with H_2O , and dried in air overnight. The solid was further dried in a rotary evaporator whose bath was heated for 2 h at 80 °C, finally giving crude **6** (11.25 g). Because of its low solubility, this material was used for the next step without further purification.

Synthesis of 4,8-Dibromo-2,6-diphenyl-1,5-dihydrobenzo[1,2-*d*:4,5-*d'*]diimidazole (7). A 250 mL round-bottom flask was charged with DMF (165 mL), and the solvent was stirred vigorously while the ground powder of compound **6** (10.8 g, 34.7 mmol) was added to it. *N*-Bromosuccinimide (NBS, 12.3 g, 69.3 mmol) was added next, and the reaction mixture was stirred at 20 °C for 1 h. The formed precipitate was filtered under reduced pressure, washed with EtOH, and dried in air to obtain 13 g of a white powder, which was identified as the target compound **7** (mp >350 °C). The overall yield for the synthesis of compound **7** from compound **5** in two steps was 80%. IR (neat): 3160 (w, $\tilde{\nu}_{\text{N-H}}$), 1560 (m, $\tilde{\nu}_{\text{C=N}}$), 1480 (s), 1460 (s), 1330 (m, $\tilde{\nu}_{\text{C-N}}$), 1280 (s), 1230 (s), 867 (s), 772 (m), 725 (s), 685 (s, $\tilde{\nu}_{\text{C-Br}}$) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ 13.01 (s, 2H), 8.32 (m, 4H), 7.53 (m, 6H) ppm. ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): δ 153.6, 153.3, 140.4, 139.9, 133.1, 132.6, 130.9, 130.0, 129.3, 127.9, 90.9 ppm. HRMS ($\text{CI}/[\text{M}]^+$): calcd for $\text{C}_{20}\text{H}_{12}\text{Br}_2\text{N}_4$ 465.9429, found 465.9435.

Synthesis of 2,6-Diphenyl-4,8-bis((triisopropylsilyl)ethynyl)-1,5-dihydrobenzo[1,2-*d*:4,5-*d'*]diimidazole. A 500 mL pear-shaped Schlenk flask was charged with compound **7** (13.0 g, 27.8 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (1.95 g, 2.77 mmol), and CuI (1.06 g, 5.56 mmol). The flask was sealed, evacuated, and backfilled with N_2 three times. In a separate flask, a mixture of (*i*-Pr) $_2\text{NH}$ (200 mL), DMF (100 mL), and (triisopropylsilyl)acetylene (TIPSA, 25 mL, 111 mmol) was degassed for 20 min and then slowly transferred, under positive N_2 pressure, via cannula to the reaction flask. The reaction mixture was stirred and heated at 90 °C for 2 d and then cooled to 20 °C. Afterward, silica gel (150 mL) was added to the reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was subjected to column chromatography on silica gel using a mixture of CH_2Cl_2 and hexane as an eluent (starting with a 1:1 volume ratio, and proceeding until 7:3 ratio). The solvent was removed in vacuo to give a yellow crude product which was further purified by recrystallization from EtOH (150 mL), finally giving the desired product as a bright yellow powder (16.4 g, mp 310 °C). IR (neat): 3460 (s, $\tilde{\nu}_{\text{N-H}}$), 2940 (s, $\tilde{\nu}_{\text{C-H}}$), 2860 (s), 2140 (m, $\tilde{\nu}_{\text{C}\equiv\text{C}}$), 1480 (m, $\tilde{\nu}_{\text{Si-C}}$), 1450 (s), 1330 (s, $\tilde{\nu}_{\text{Si-C}}$), 997 (w), 883 (w), 775 (w), 740 (s), 668 (s) cm^{-1} . ^1H NMR (CDCl_3 , 500 MHz): δ 9.43 (s, 2H), 8.08 (d, $^3J_{\text{H-H}} = 6.9$ Hz, 4H), 7.52 (m, 6H), 1.27 (m, 42H) ppm. ^{13}C NMR (CDCl_3 , 125 MHz): δ 152.3, 151.8, 142.7, 141.9, 134.4, 133.7, 130.5, 130.3, 129.6, 129.2, 129.1, 126.7, 102.2, 99.8, 97.1,

19.0, 18.9, 11.7, 11.5, 11.3 ppm. HRMS (CI/[M]⁺): calcd for C₄₂H₅₄N₄Si₂⁺ 670.3887, found 670.3871.

Synthesis of 4,8-Diethynyl-2,6-diphenyl-1,5-dihydrobenzo-[1,2-d:4,5-d']diimidazole (8). In a nitrogen-flushed 100 mL flask was dissolved tris(isopropyl)silyl-substituted alkyne produced in the previous step (2.00 g, 2.98 mmol) in THF (20 mL), and the mixture was treated with a 1 M solution of TBAF in THF (6.56 mL, 6.56 mmol). The resulting solution was stirred at 20 °C for 1 h, and a yellow precipitate was formed. The precipitate was collected by filtration and washed with THF. The residue was mixed with H₂O (150 mL) and sonicated for 10 min to give fraction A. Meanwhile, the solvent in the filtrate was removed under reduced pressure. The remaining solid was mixed with EtOH (10 mL), followed by H₂O (40 mL), to give fraction B. Subsequently, fraction A was combined with fraction B. The mixture was sonicated for 10 min, filtered, washed with H₂O, and dried in vacuo to yield 1.06 g of crude **8** as a dark yellow powder, which was used in the next step without purification. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 13.03 (s, 2H), 8.32 (d, *J* = 6.9 Hz, 4H), 7.52 (m, 6H), 4.88 (m, 2H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz): δ 153.5, 153.2, 143.0, 142.7, 134.8, 134.5, 130.6, 130.3, 129.3, 127.8, 95.8, 91.4, 90.6, 90.0, 78.3 ppm.

Synthesis of Cruciform 4a. Phenylacetylene (781 mg, 7.65 mmol) was added to a thick-walled microwave pressure vial that contained a mixture of compound **7** (300 mg, 0.64 mmol), PdCl₂(PPh₃)₂ (90 mg, 0.13 mmol), CuI (45 mg, 0.24 mmol), Et₃N (5 mL), and DMF (5 mL). The vial was sealed under nitrogen and exposed to microwave irradiation for 12 h at 110 °C. After cooling, the reaction mixture was extracted with EtOAc, washed with brine, and dried over anhydrous MgSO₄. Afterward, Al₂O₃ (80 g) was added to the combined organic layer and the solvent was removed under reduced pressure until a brown powder formed, which was purified by gradient elution column chromatography on alumina (300 g) using EtOAc and hexane as eluents (starting volume ratio 3:17, ending volume ratio 9:11). The solvent was removed in vacuo to yield the crude product which was further purified by recrystallization from THF to give **4a** as a yellow powder (153 mg, 47%, mp 309 °C dec). UV/vis (THF): λ_{max} (log ε) 386 (4.90) nm. IR (neat): 3056 (w, $\tilde{\nu}_{\text{N-H}}$), 2160 (w, $\tilde{\nu}_{\text{C}\equiv\text{C}}$), 1958 (w), 1596 (m, $\tilde{\nu}_{\text{C}=\text{N}}$), 1557 (w), 1526 (w), 1476 (s), 1454 (s), 1441 (w), 1402 (m), 1342 (s), 1280 (m), 1215 (w), 1177 (w), 1156 (w), 1115 (w), 1069 (m), 1028 (m), 999 (w), 943 (m), 913 (w), 775 (m), 752 (s), 728 (m), 686 (s), 624 (s), 565 (m) cm⁻¹. ¹H NMR (DMSO-*d*₆, 600 MHz): δ 12.96 (s, 2H), 8.34 (d, ³*J*_{H-H} = 7.6 Hz, 4H), 7.78 (m, 4H), 7.56 (t, ³*J*_{H-H} = 7.6 Hz, 4H), 7.51 (m, 8H) ppm. ¹³C NMR (DMSO-*d*₆, 150 MHz, 40 °C): δ 153.5, 142.6, 134.0, 130.5, 129.3, 127.9, 123.7, 103.7, 98.7, 96.6, 89.9, 86.4, 84.6, 82.9 ppm. HRMS (ESI/[M]⁺): calcd for C₃₆H₂₂N₄⁺ 510.1844, found 510.1849.

Synthesis of Cruciform 4b. Anhydrous K₂CO₃ (1.11 g, 8.00 mmol) was added to a solution of 2-(4-(*N,N*-dimethylamino)phenyl)-(trimethylsilyl)ethyne (875 mg, 4.00 mmol) in a mixture of MeOH (5 mL) and THF (5 mL). After being stirred for 30 min under nitrogen, the reaction mixture was filtered through Celite. The solvent was removed under reduced pressure to yield crude 4-ethynyl-*N,N*-dimethylaniline, which was used without purification in the next step. To minimize manipulations of this compound, we assumed a 95% yield for this reaction.^{4g}

The entire amount of 4-ethynyl-*N,N*-dimethylaniline (prepared as described above) was added to a thick-walled microwave pressure vial that contained a mixture of compound **7** (300 mg, 0.64 mmol), PdCl₂(PPh₃)₂ (90 mg, 0.13 mmol), CuI (45 mg, 0.24 mmol), Et₃N (5 mL), and DMF (5 mL). The vial was sealed under nitrogen and exposed to microwave irradiation for 12 h at 100 °C. After cooling, the reaction mixture was extracted with EtOAc, washed with brine, and dried over anhydrous MgSO₄. Afterward, 80 g of aluminum oxide was added to the combined organic layer, and the solvent was removed under reduced pressure until a brown powder was formed, which was purified by gradient elution column chromatography on alumina, using EtOAc/hexane eluent system (solvent ratios ranging from 4:16 to 9:11). The solvent was removed in vacuo to give the crude product, which was further purified by recrystallization from THF to afford 214

mg (56%, 0.36 mmol) of a tangelo-colored powder (**4b**, mp 220 °C dec). UV/vis (THF): λ_{max} (log ε) 386 (4.81), 425 (4.70) nm. IR (neat): 3086 (w, $\tilde{\nu}_{\text{N-H}}$), 2190 (s, $\tilde{\nu}_{\text{C}\equiv\text{C}}$), 1604 (s, $\tilde{\nu}_{\text{C}=\text{N}}$), 1530 (m), 1514 (m), 1479 (m), 1457 (m), 1402 (w), 1345 (s), 1290 (m), 1232 (m), 1183 (s), 1065 (m), 1029 (m), 999 (w), 945 (m), 920 (w), 843 (w), 810 (s), 777 (m), 725 (m), 690 (s), 634 (w), 580 (w) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 12.90 (d, ³*J*_{H-H} = 5.2 Hz, 2H), 8.34 (m, 4H), 8.57 (m, 10H), 6.79 (d, ³*J*_{H-H} = 8.6 Hz, 4H), 2.98 (s, 12H) ppm. ¹³C NMR (DMSO-*d*₆, with 20 mg of TBAF trihydrate added, 150 MHz): δ 159.5, 149.3, 146.5, 139.9, 132.1, 127.9, 126.6, 125.3, 114.0, 112.8, 96.1, 94.0, 91.8, 51.9 ppm. HRMS (ESI/[M]⁺): calcd for C₄₀H₃₂N₆⁺ 596.2688, found 596.2692.

Synthesis of Cruciform 4c. A mixture of compound **8** (300 mg, 0.84 mmol), 4-iodotoluene (913 mg, 4.19 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was added to a 100 mL pear-shaped Schlenk flask. The flask was sealed, and then evacuated and backfilled with nitrogen three times. In a separate flask, a mixture of Et₃N (25 mL) and THF (17 mL) was degassed for 30 min and transferred slowly under positive N₂ pressure via cannula to the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C. Afterward, aluminum oxide was added to the reaction mixture and the solvent was removed under reduced pressure until a brown powder was formed, which was subsequently purified by gradient elution column chromatography on alumina, using EtOAc/hexane eluent system (volume ratios ranging from 3:17 to 9:11). The solvent was removed in vacuo to give the crude product, which was further purified by recrystallization from THF to afford cruciform **4c** as a yellow powder (174 mg, 38%, mp 293 °C). UV/vis (THF): λ_{max} (log ε) 386 (4.91) nm. IR (neat): 3000 (w, $\tilde{\nu}_{\text{N-H}}$), 2188 (w, $\tilde{\nu}_{\text{C}\equiv\text{C}}$), 1603 (m, $\tilde{\nu}_{\text{C}=\text{N}}$), 1560 (w), 1528 (w), 1505 (m), 1480 (s), 1454 (s), 1401 (m), 1336 (s), 1286 (m), 1254 (m), 1236 (m), 1176 (m), 1109 (w), 1070 (w), 1030 (m), 987 (w), 935 (m), 809 (s), 774 (s), 738 (w), 723 (m), 692 (s), 632 (w) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 12.97 (s, 2H), 8.34 (d, ³*J*_{H-H} = 7.5 Hz, 4H), 8.57 (m, 10H), 7.32 (d, ³*J*_{H-H} = 5.7 Hz, 4H), 2.38 (s, 6H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz, 90 °C): δ 153.3, 138.9, 132.1, 130.7, 130.5, 129.8, 129.2, 128.0, 120.9, 21.6 ppm. HRMS (ESI/[M]⁺): calcd for C₃₈H₂₆N₄⁺ 538.2157, found 538.2138.

Synthesis of Cruciform 4d. A mixture of compound **8** (300 mg, 0.84 mmol), 4-iodoanisole (979 mg, 4.19 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was added to a 100 mL pear-shaped Schlenk flask. The flask was sealed, then evacuated and backfilled with nitrogen three times. In a separate flask, a mixture of Et₃N (25 mL) and THF (17 mL) was degassed for 30 min and transferred slowly under positive N₂ pressure via cannula to the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C. Afterward, 80 g of aluminum oxide was added to the reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was purified by gradient elution column chromatography on alumina, using EtOAc/hexane eluent system (volume ratio ranging from 7:13 to 4:1). The solvent was removed in vacuo to give the crude product, which was further purified by recrystallization from THF to afford cruciform **4d** as a yellow powder (196 mg, 41%, mp 280 °C). UV/vis (THF): λ_{max} (log ε) 385 (4.93) nm. IR (neat): 3062 (w, $\tilde{\nu}_{\text{N-H}}$), 2834 (w, $\tilde{\nu}_{\text{C-H}}$), 2195 (m, $\tilde{\nu}_{\text{C}\equiv\text{C}}$), 1603 (s, $\tilde{\nu}_{\text{C}=\text{N}}$), 1567 (w), 1524 (w), 1504 (s), 1478 (s), 1453 (s), 1399 (m), 1340 (s), 1288 (s), 1244 (s), 1169 (s), 1106 (m), 1071 (w), 1027 (s), 942 (m), 827 (s), 774 (s), 727 (s), 689 (s), 644 (w), 633 (w), 589 (s), 564 (m), 546 (m), 529 (s) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz at 90 °C): δ 12.69 (s, 2H), 8.33 (d, ³*J*_{H-H} = 6.9 Hz, 4H), 7.71 (s, 4H), 7.52 (m, 6H), 7.05 (d, ³*J*_{H-H} = 8.6 Hz, 4H), 3.84 (s, 6H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz, 90 °C): δ 160.4, 153.2, 142.0, 133.7, 130.7, 130.4, 129.1, 128.0, 116.0, 115.0, 98.9, 96.9, 83.4, 56.0 ppm. HRMS (ESI/[M]⁺): calcd for C₃₈H₂₆N₄O₂⁺ 570.2056, found 570.2056.

Synthesis of Cruciform 4e. A mixture of compound **8** (300 mg, 0.84 mmol), 4-fluoroiodobenzene (0.56 mL, 4.85 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was added to a 100 mL pear-shaped Schlenk flask. The flask was sealed and then evacuated and backfilled with nitrogen three times. In a

separate flask, a mixture of Et₃N (25 mL) and THF (17 mL) was degassed for 30 min and then transferred slowly under positive N₂ pressure via cannula to the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C. Afterward, alumina was added to reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was then purified by gradient elution column chromatography on alumina using EtOAc/hexane eluent system (volume ratio ranging from 1:3 to 1:1). The solvent was removed to give the orange crude product, which was further purified by recrystallization from EtOAc, to afford cruciform **4e** (187 mg, 41%, mp 287 °C). UV/vis (THF): λ_{max} (log ϵ) 383 (4.89) nm. IR (neat): 3066 (w, $\nu_{\text{N-H}}$), 2158 (w, $\nu_{\text{C}\equiv\text{C}}$), 1602 (m, $\nu_{\text{C=N}}$), 1558 (w), 1525 (w), 1503 (s), 1477 (s), 1455 (s), 1402 (m), 1342 (s), 1317 (w), 1288 (s), 1235 (s), 1169 (s), 1105 (m), 1064 (w), 1028 (s), 943 (m), 832 (s), 775 (s), 747 (w), 728 (m), 689 (s), 634 (w), 582 (s), 566 (w), 556 (w), 547 (w), 530 (s) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 13.05 (d, ³*J*_{H-H} = 8.0 Hz, 2H), 8.33 (m, 4H), 7.84 (m, 4H), 7.55 (m, 6H), 7.36 (m, 4H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz): δ 163.7, 161.6, 153.4, 142.3, 134.5, 130.7, 129.3, 127.7, 120.0, 116.6, 97.6, 96.4, 84.3 ppm. HRMS (ESI/[M]⁺): calcd for C₃₆H₂₀F₂N₄⁺ 546.1656, found 546.1656.

Synthesis of Cruciform 4f. A mixture of compound **8** (300 mg, 0.84 mmol), 1-iodo-4-nitrobenzene (834 mg, 3.35 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was placed in a 100 mL pear-shaped Schlenk flask. The flask was sealed and then evacuated and backfilled with nitrogen three times. In a separate flask, a mixture of Et₃N (30 mL) and THF (20 mL) was degassed for 30 min and then transferred slowly under positive nitrogen pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 50 °C for 24 h, cooled to 20 °C, filtered, and washed with THF (5 mL). The residue collected was recrystallized from THF to give the crude product, which was then mixed with H₂O (150 mL), sonicated for 30 min, filtered, and dried in air to give cruciform **4f** (136 mg, 27%) as a red powder (mp 327 °C dec). UV/vis (THF): λ_{max} (log ϵ) 388 (4.80) nm. IR (neat): 3060 (w, $\nu_{\text{N-H}}$), 2199 (w, $\nu_{\text{C}\equiv\text{C}}$), 1591 (m, $\nu_{\text{C=N}}$), 1514 (s, ν_{NO_2}), 1476 (m), 1454 (m), 1402 (w), 1337 (s, ν_{NO_2}), 1175 (w), 1106 (m), 1028 (w), 994 (w), 943 (w), 854 (s), 775 (m), 748 (m), 728 (w), 687 (s), 568 (w) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 13.29 (s, 2H), 8.34 (apparent d, ³*J*_{H-H} = 6.9 Hz, 8H), 8.01 (br s, 4H), 7.57 (m, 6H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz): δ 133.2, 131.1, 130.0, 129.5, 128.1, 124.4 ppm (because of the low solubility of cruciform **4f**, a satisfactory ¹³C NMR spectrum could not be obtained; listed are all the observed peaks). HRMS (ESI/[M]⁺): calcd for C₃₆H₂₀N₆O₄⁺ 600.1546, found 600.1526.

Synthesis of Cruciform 4g. A mixture of compound **8** (300 mg, 0.84 mmol), 4-iodobenzotrifluoride (0.50 mL, 3.40 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was placed in a 100 mL pear-shaped Schlenk flask. The flask was sealed and then evacuated and backfilled with nitrogen three times. A mixture of Et₃N (30 mL) and THF (20 mL) was degassed for 30 min and transferred slowly under positive nitrogen pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C. Afterward, silica gel was added to the reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was purified by gradient elution column chromatography on silica gel, using the EtOAc/hexane eluent system (volume ratio ranging from 1:3 to 1:1). The solvent was removed in vacuo to give the yellow crude product, which was further purified by recrystallization from Et₂O to yield cruciform **4g** (220 mg, 41%) as a yellow powder (mp 245 °C dec). UV/vis (THF): λ_{max} (log ϵ) 392 (4.86) nm. IR (neat): 3062 (w, $\nu_{\text{N-H}}$), 2201 (w, $\nu_{\text{C}\equiv\text{C}}$), 1613 (m, $\nu_{\text{C=N}}$), 1563 (w), 1529 (w), 1505 (w), 1478 (s), 1455 (s), 1403 (m), 1341 (s), 1317 (s), 1290 (s), 1246 (m), 1167 (s), 1119 (s), 1103 (s), 1064 (s), 1028 (s), 1018 (s), 945 (m), 837 (s), 774 (s), 747 (w, ν_{CF_3}), 728 (m), 689 (s), 634 (w), 592 (s), 537 (m) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 13.16 (s, 2H), 8.34 (d, ³*J*_{H-H} = 7.5 Hz, 4H), 8.00 (m, 8H), 7.55 (m, 6H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz): δ 153.5, 142.6, 134.2, 132.9, 130.9,

130.2, 129.4, 127.9, 126.2, 125.7, 123.5, 97.4, 96.3, 87.1 ppm. HRMS (ESI/[M]⁺): calcd for C₃₈H₂₀F₆N₄⁺ 646.1592, found 646.1592.

Synthesis of Cruciform 4h. A mixture of compound **8** (300 mg, 0.84 mmol), 2-iodothiophene (0.55 mL, 4.98 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was placed in a 100 mL pear-shaped Schlenk flask. The flask was sealed, evacuated, and backfilled with nitrogen three times. A solution of Et₃N (25 mL) and THF (17 mL) was degassed for 30 min and then transferred slowly under positive nitrogen pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C. Afterward, alumina was added to the reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was purified by gradient elution column chromatography on alumina using EtOAc/hexane eluent system (volume ratio ranging from 1:4 to 3:2). The solvent was removed in vacuo to give the crude product, which was further purified by recrystallization from THF/hexane to yield cruciform **4h** (153 mg, 35%) as a dark yellow powder (mp 268 °C dec). UV/vis (THF): λ_{max} (log ϵ) 391 (4.89) nm. IR (neat): 3111 (w, $\nu_{\text{C-H}}$ thiophene), 3060 (w, $\nu_{\text{N-H}}$), 2190 (w, $\nu_{\text{C}\equiv\text{C}}$), 1613 (w, $\nu_{\text{C=N}}$), 1562 (w), 1531 (w), 1506 (w), 1479 (m), 1454 (s), 1396 (w), 1341 (s), 1325 (s), 1276 (m), 1226 (s), 1174 (w), 1071 (w), 1043 (s), 1029 (m), 965 (w), 942 (m), 918 (w), 851 (s), 831 (m), 774 (s), 744 (w), 686 (s), 625 (m) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz): δ 13.12 (s, 2H), 8.32 (d, ³*J*_{H-H} = 7.5 Hz, 4H), 8.56 (m, 10H), 7.20 (m, 2H) ppm. ¹³C NMR (Me₂CO-*d*₆ and 200 mg of TBAF trihydrate, 150 MHz): δ 131.2, 128.0, 127.2, 127.1, 126.2, 125.8, 88.7 ppm. HRMS (ESI/[M]⁺): calcd for C₃₂H₁₈N₄S₂⁺ 522.0973, found 522.0959.

Synthesis of Cruciform 4i. A mixture of compound **8** (300 mg, 0.84 mmol), 4-iodoacetophenone (618 mg, 2.51 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was placed in a 100 mL pear-shaped Schlenk flask. The flask was sealed and then evacuated and backfilled with nitrogen three times. In a separate flask, a mixture of Et₃N (30 mL) and THF (20 mL) was degassed for 30 min and transferred slowly under positive nitrogen pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 65 °C for 2 d, cooled to 20 °C, filtered, and washed with THF (5 mL). The residue collected was recrystallized from THF to give the crude product, which was mixed with H₂O (150 mL), sonicated for 30 min, filtered, and dried in air to give cruciform **4i** (300 mg, 60%) as a yellow powder (mp 352 °C dec). UV/vis (THF): λ_{max} (log ϵ) 382 (4.60) nm. IR (neat): 3199 (w, $\nu_{\text{N-H}}$), 2204 (w, $\nu_{\text{C}\equiv\text{C}}$), 1668 (s), 1602 (s, $\nu_{\text{C=N}}$), 1557 (w), 1505 (w), 1480 (m), 1455 (s), 1402 (m), 1336 (s), 1312 (w), 1273 (s), 1168 (m), 1105 (m), 1064 (m), 1029 (m), 1017 (w), 940 (w), 829 (s), 777 (s), 747 (w), 728 (m), 689 (s), 593 (m) cm⁻¹. ¹H NMR (DMSO-*d*₆, 500 MHz, 40 °C): δ 13.10 (s, 2H), 8.35 (d, ³*J*_{H-H} = 6.9 Hz, 4H), 8.06 (d, ³*J*_{H-H} = 7.5 Hz, 4H), 7.90 (s, 4H), 7.55 (m, 6H), 2.62 (s, 6H) ppm. ¹³C NMR (DMSO-*d*₆, 125 MHz, 40 °C): δ 197.8, 154.1, 136.8, 132.3, 130.8, 130.3, 129.3, 129.0, 128.0, 98.3, 27.3 ppm (because of the low solubility of cruciform **4i**, a satisfactory ¹³C NMR spectrum could not be obtained; listed are all the observed peaks). HRMS (ESI/[M]⁺): calcd for C₄₀H₂₆N₄O₂⁺ 594.2056, found 594.2050.

Synthesis of Cruciform 4j. A mixture of compound **8** (300 mg, 0.84 mmol), ethyl 4-iodobenzoate (0.56 mL, 3.33 mmol), PdCl₂(PPh₃)₂ (50 mg, 0.07 mmol), and CuI (27 mg, 0.14 mmol) was added to a 100 mL pear-shaped Schlenk flask. The flask was sealed and then evacuated and backfilled with nitrogen three times. In a separate flask, a solution of Et₃N (30 mL) and THF (20 mL) was degassed for 30 min and then transferred slowly under positive nitrogen pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 65 °C for 24 h and then cooled to 20 °C, filtered, and washed with THF (5 mL). The residue collected was recrystallized from a THF/EtOAc mixture (volume ratio 2:3) to give the crude product which was then mixed with H₂O (150 mL), sonicated for 30 min, filtered, and dried in air to finally give cruciform **4j** (310 mg, 57%) as a yellow powder (mp 268 °C dec). UV/vis (THF): λ_{max} (log ϵ) 394 (4.89) nm. IR (neat): 3253 (m), 2981 (w, $\nu_{\text{N-H}}$), 2205 (w, $\nu_{\text{C}\equiv\text{C}}$), 1694 (s, $\nu_{\text{C=O}}$), 1605 (m, $\nu_{\text{C=N}}$), 1561 (w), 1524 (w), 1504 (m), 1480 (s), 1454 (s), 1404 (m), 1365 (w), 1339

(s), 1308 (w), 1287 (s, $\nu_{\text{CO-O}}$), 1275 (s), 1172 (m), 1128 (m), 1106 (s), 1071 (w), 1021 (m), 987 (w), 941 (m), 853 (m), 830 (w), 773 (s), 765 (m), 725 (m), 687 (s), 652 (w) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$, 400 MHz): δ 13.15 (d, $^3J_{\text{H-H}} = 5.0$ Hz, 2H), 8.35 (m, 4H), 8.00 (m, 8H), 7.55 (m, 6H), 4.33 (q, $^3J_{\text{H-H}} = 7.3$ Hz, 4H), 1.33 (t, $^3J_{\text{H-H}} = 7.3$ Hz, 6H) ppm. ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz): δ 165.8, 153.6, 142.7, 134.1, 132.4, 130.9, 130.2, 129.9, 129.4, 128.0, 98.1, 96.3, 87.6, 61.6, 14.7 ppm. HRMS (ESI/[M] $^+$): calcd for $\text{C}_{42}\text{H}_{30}\text{N}_4\text{O}_4^+$ 654.2267, found 654.2270.

Synthesis of Cruciform 4l. A mixture of compound **8** (500 mg, 1.39 mmol), 4-(iodophenyl)tetrahydropyran-2-yl ether¹⁶ (1.73 g, 5.58 mmol), $\text{PdCl}_2(\text{PPh}_3)_2$ (83 mg, 0.12 mmol), and CuI (45 mg, 0.24 mmol) was added to a 100 mL pear-shaped Schlenk flask. The flask was sealed, evacuated, and backfilled with nitrogen three times. In a separate flask, a solution of Et_3N (40 mL) and THF (27 mL) was degassed for 30 min and then transferred slowly under positive N_2 pressure via cannula into the reaction flask. The reaction mixture was stirred and heated at 60 °C for 36 h and then cooled to 20 °C. Afterward, alumina was added to the reaction mixture, and the solvent was removed under reduced pressure until a brown powder was formed. This powder was purified by gradient elution column chromatography on alumina using EtOAc /hexane eluent system (volume ratio ranging from 25:75 to 55:45). The solvent was removed in vacuo to give 590 mg of the crude cruciform **4k** as the intermediate.

In a 250 mL round-bottom flask was added trifluoroacetic acid (4.5 mL) to a solution of the aforementioned cruciform **4k** (590 mg, 0.83 mmol) in DCM (150 mL), which was kept in a dry ice/ Me_2CO bath. The reaction was stirred for 2 h at -78 °C and then warmed to 20 °C.¹⁷ The precipitate formed in the reaction was collected by filtration and washed with DCM. Afterward, it was mixed with water (500 mL), sonicated for 30 min, filtered, and dried in air to give the crude product, which was further purified by recrystallization from THF to afford cruciform **4l** (310 mg, 41%) as a yellow powder (mp 320 °C dec). UV/vis (THF): λ_{max} (log ϵ) 383 (4.95) nm. IR (neat): 3410 (w, $\nu_{\text{O-H}}$), 3063 (w, $\nu_{\text{N-H}}$), 2204 (w, $\nu_{\text{C}\equiv\text{C}}$), 1604 (s, $\nu_{\text{C}\equiv\text{N}}$), 1525 (w), 1505 (s), 1479 (s), 1454 (s), 1402 (w), 1380 (w), 1345 (m), 1278 (m), 1265 (w), 1243 (s), 1169 (s), 1105 (w), 1072 (w), 1028 (m), 946 (w), 828 (s), 776 (s), 727 (w), 692 (s), 684 (s), 634 (w), 616 (w), 591 (s), 567 (w), 534 (s) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$, 500 MHz): δ 12.95 (s, 2H), 9.97 (s, 2H), 8.33 (d, $^3J_{\text{H-H}} = 7.5$ Hz, 4H), 8.52 (m, 10H), 6.87 (d, $^3J_{\text{H-H}} = 8.0$ Hz, 4H) ppm. ^{13}C NMR ($\text{DMSO}-d_6$, 125 MHz): δ 158.7, 153.1, 142.4, 133.9, 130.6, 129.3, 127.8, 116.3, 113.9, 99.4, 96.6, 82.5 ppm. HRMS (ESI/[M] $^+$): calcd for $\text{C}_{36}\text{H}_{22}\text{N}_4\text{O}_2^+$ 542.1743, found 542.1742.

■ ASSOCIATED CONTENT

■ Supporting Information

Additional experimental and computational details and spectroscopic characterization data. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b00616.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: miljanic@uh.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by the University of Houston (UH), a Grant to Advance and Enhance Research from the National Science Foundation (Grant No. CHE-1151292 to O.Š.M.), and the Welch Foundation (Grant No. E-1768 to O.Š.M.). O.Š.M. is a Cottrell Scholar of the Research Corporation for Science Advancement. N.S.E. acknowledges the Texas Center for Superconductivity at UH (TcSUH) for a Paul C. W. Chu scholarship. Parts of this manuscript were written at New

York University Abu Dhabi (NYUAD), where O.Š.M. was on a sabbatical stay.

■ REFERENCES

- (1) For selected examples of different cruciform motifs, see: (a) Bhaskar, A.; Guda, R.; Haley, M. M.; Goodson, T., III. *J. Am. Chem. Soc.* **2006**, *128*, 13972–13973. (b) Marsden, J. A.; Miller, J. J.; Shirtcliff, L. D.; Haley, M. M. *J. Am. Chem. Soc.* **2005**, *127*, 2464–2476. (c) Davey, E. A.; Zuccherro, A. J.; Trapp, O.; Bunz, U. H. F. *J. Am. Chem. Soc.* **2011**, *133*, 7716–7718. (d) McGrier, P. L.; Solntsev, K. M.; Zuccherro, A. J.; Miranda, O. R.; Rotello, V. M.; Tolbert, L. M.; Bunz, U. H. F. *Chem.—Eur. J.* **2011**, *17*, 3112–3119. (e) Zuccherro, A. J.; McGrier, P. L.; Bunz, U. H. F. *Acc. Chem. Res.* **2010**, *43*, 397–408. (f) Tolosa, J.; Zuccherro, A. J.; Bunz, U. H. F. *J. Am. Chem. Soc.* **2008**, *130*, 6498–6506. (g) Zuccherro, A. J.; Wilson, J. N.; Bunz, U. H. F. *J. Am. Chem. Soc.* **2006**, *128*, 11872–11881. (h) Kang, H.; Evmenenko, G.; Dutta, P.; Clays, K.; Song, K.; Marks, T. J. *J. Am. Chem. Soc.* **2006**, *128*, 6194–6205. (i) Kang, H.; Zhu, P.; Yang, Y.; Facchetti, A.; Marks, T. J. *J. Am. Chem. Soc.* **2004**, *126*, 15974–15975. (j) Gisselbrecht, J. P.; Moonen, N. N. P.; Boudon, C.; Nielsen, M. B.; Diederich, F.; Gross, M. *Eur. J. Org. Chem.* **2004**, 2959–2972. (k) Mitzel, F.; Boudon, C.; Gisselbrecht, J. P.; Seiler, P.; Gross, M.; Diederich, F. *Helv. Chim. Acta* **2004**, *87*, 1130–1157. (l) Hilger, A.; Gisselbrecht, J.-P.; Tykwinski, R. R.; Boudon, C.; Schreiber, M.; Martin, R. E.; Lüthi, H. P.; Gross, M.; Diederich, F. *J. Am. Chem. Soc.* **1997**, *119*, 2069–2078. (m) Koenen, J.-M.; Bilge, A.; Allard, S.; Alle, R.; Meerholz, K.; Scherf, U. *Org. Lett.* **2009**, *11*, 2149–2152. (n) Zen, A.; Bilge, A.; Galbrecht, F.; Alle, R.; Meerholz, K.; Grenzer, J.; Neher, D.; Scherf, U.; Farrell, T. *J. Am. Chem. Soc.* **2006**, *128*, 3914–3915.
- (2) (a) Feldman, A. K.; Steigerwald, M. L.; Guo, X.; Nuckolls, C. *Acc. Chem. Res.* **2008**, *41*, 1731–1741. (b) Tang, J.; Wang, Y.; Klare, J. E.; Tulevski, G. S.; Wind, S. J.; Nuckolls, C. *Angew. Chem., Int. Ed.* **2007**, *46*, 3892–3895. (c) Florio, G. M.; Klare, J. E.; Pasamba, M. O.; Werblowsky, T. L.; Hyers, M.; Berne, B. J.; Hybertsen, M. S.; Nuckolls, C.; Flynn, G. W. *Langmuir* **2006**, *22*, 10003–10008. (d) Guo, X.; Small, J. P.; Klare, J. E.; Wang, Y.; Purewal, M. S.; Tam, I. W.; Hong, B. H.; Caldwell, R.; Huang, L.; O'Brien, S.; Yan, J.; Breslow, R.; Wind, S. J.; Hone, J.; Kim, P.; Nuckolls, C. *Science* **2006**, *311*, 356–359. (e) de Picciotto, A.; Klare, J. E.; Nuckolls, C.; Baldwin, K.; Erbe, A.; Willett, R. *Nanotechnology* **2005**, *16*, 3110–3114. (f) Klare, J. E.; Tulevski, G. S.; Nuckolls, C. *Langmuir* **2004**, *20*, 10068–10072. (g) Klare, J. E.; Tulevski, G. S.; Sugo, K.; de Picciotto, A.; White, K. A.; Nuckolls, C. *J. Am. Chem. Soc.* **2003**, *125*, 6030–6031.
- (3) (a) Tlach, B. C.; Tomlinson, A. L.; Morgan, K. D.; Collins, C. R.; Jeffries-EL, M. *Aust. J. Chem.* **2014**, *67*, 711–721. (b) Tlach, B. C.; Tomlinson, A. L.; Ryno, A. G.; Knoble, D. D.; Drochner, D. L.; Krager, K. J.; Jeffries-EL, M. *J. Org. Chem.* **2013**, *78*, 6570–6581. (c) Intemann, J. J.; Hellerich, E. S.; Tlach, B. C.; Ewan, M. D.; Barnes, C. A.; Bhuwanka, A.; Cai, M.; Shinar, J.; Shinar, R.; Jeffries-EL, M. *Macromolecules* **2012**, *45*, 6888–6897. (d) Klimavicz, J. S.; Mike, J. F.; Bhuwanka, A.; Tomlinson, A. L.; Jeffries-EL, M. *Pure Appl. Chem.* **2012**, *84*, 991–1004. (e) Tlach, B. C.; Tomlinson, A. L.; Bhuwanka, A.; Jeffries-EL, M. *J. Org. Chem.* **2011**, *76*, 8670–8681. (f) Mike, J. F.; Makowski, A. J.; Jeffries-EL, M. *Org. Lett.* **2008**, *10*, 4915–4918.
- (4) (a) Saeed, M. A.; Le, H. T. M.; Miljanić, O. Š. *Acc. Chem. Res.* **2014**, *47*, 2074–2083. (b) Martínez-Martínez, V.; Lim, J.; Bañuelos, J.; López-Arbeloa, I.; Miljanić, O. Š. *Phys. Chem. Chem. Phys.* **2013**, *15*, 18023–18029. (c) Jo, M.; Lim, J.; Miljanić, O. Š. *Org. Lett.* **2013**, *15*, 3518–3521. (d) Lim, J.; Miljanić, O. Š. *Chem. Commun.* **2012**, *48*, 10301–10303. (e) Lim, J.; Osowska, K.; Armitage, J. A.; Martin, B. R.; Miljanić, O. Š. *CrystEngComm* **2012**, *14*, 6152–6162. (f) Lim, J.; Nam, D.; Miljanić, O. Š. *Chem. Sci.* **2012**, *3*, 559–563. (g) Lim, J.; Albright, T. A.; Martin, B. R.; Miljanić, O. Š. *J. Org. Chem.* **2011**, *76*, 10207–10219. (h) Osowska, K.; Miljanić, O. Š. *Chem. Commun.* **2010**, *46*, 4276–4278.
- (5) Lirag, R. C.; Le, H. T. M.; Miljanić, O. Š. *Chem. Commun.* **2013**, *49*, 4304–4306.
- (6) (a) Boydston, A. J.; Pecinovsky, C. S.; Chao, S. T.; Bielawski, C. W. *J. Am. Chem. Soc.* **2007**, *129*, 14550–14551. (b) Boydston, A. J.

Vu, P. D.; Dykhno, O. L.; Chang, V.; Wyatt, A. R., II; Stockett, A. S.; Ritschdorff, E. T.; Shear, J. B.; Bielawski, C. W. *J. Am. Chem. Soc.* **2008**, *130*, 3143–3156. (c) Boydston, A. J.; Khramov, D. M.; Bielawski, C. W. *Tetrahedron Lett.* **2006**, *47*, 5123–5125. (d) Khramov, D. M.; Boydston, A. J.; Bielawski, C. W. *Org. Lett.* **2006**, *8*, 1831–1834.

(7) Hegedus, L. S.; Odle, R. R.; Winton, P. M.; Weider, P. R. *J. Org. Chem.* **1982**, *47*, 2607–2613.

(8) (a) Zhang, L.-P.; Jiang, K.-J.; Li, G.; Zhang, Q.-Q.; Yang, L.-M. *J. Mater. Chem. A* **2014**, *2*, 14852–14857. (b) Li, H.; Kim, F. S.; Ren, G.; Hollenbeck, E. C.; Subramaniyan, S.; Jenekhe, S. A. *Angew. Chem., Int. Ed.* **2013**, *52*, 5513–5517.

(9) Nihei, M.; Kurihara, M.; Mizutani, J.; Nishihara, H. *J. Am. Chem. Soc.* **2003**, *125*, 2964–2973.

(10) Gaussian 09, Revision B.01: Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford, CT, 2010.

(11) For example, cruciform **4j** appears to have a fluorescence quantum yield of 98% (measured using 9,10-diphenylanthracene as the standard). We will elaborate on this finding and other related studies in a future paper dealing exclusively with the photophysics of benzobisimidazole cruciforms.

(12) Walba, H.; Isensee, R. W. *J. Org. Chem.* **1961**, *26*, 2789–2791.

(13) (a) Phan, A.; Doonan, C. J.; Uribe-Romo, F. J.; Knobler, C. B.; O’Keeffe, M.; Yaghi, O. M. *Acc. Chem. Res.* **2010**, *43*, 58–67. (b) Park, K. S.; Ni, Z.; Côté, A. P.; Choi, J. Y.; Huang, R. D.; Uribe-Romo, F. J.; Chae, H. K.; O’Keeffe, M.; Yaghi, O. M. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 10186–10191.

(14) Takayama, Y.; Yamada, T.; Tatekabe, S.; Nagasawa, K. *Chem. Commun.* **2013**, *49*, 6519–6521.

(15) Boyer, J. H.; Buriks, R. S.; Toggweiler, U. *J. Am. Chem. Soc.* **1960**, *82*, 2213–2215.

(16) Li, Y.; Urbas, A.; Li, Q. *J. Org. Chem.* **2011**, *76*, 7148–7156.

(17) McGrier, P. L.; Solntsev, K. M.; Schönhaber, J.; Brombosz, S. M.; Tolbert, L. M.; Bunz, U. H. F. *Chem. Commun.* **2007**, 2127–2129.